Advanced Search
CanSino Biologics

CanSino Biologics

CanSino Biologics (CanSinoBIO) is a bio pharmaceutical company primarily producing vaccines.

Would it be accurate and relevant to link the text highlighted below to the topic MontrealMontreal?

In April 2020, CanSino Biologics advanced its vaccine candidate candidate, Ad5-nCoV, into Phase II trials (Chinese registration number: ChiCTR2000030906). CanSino Biologics (CanSinoBIO) is collaborating with the National Research Council of Canada (NRC) to advance bioprocessing and clinical development of vaccine candidate against COVID-19, Ad5-nCoV. Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSinoBIO. A genetically engineering replication-defective adenovirus type 5 vector was used to express the SARS-CoV-2 spike protein which is produced in HEK293 cell lines designed and developed at the NRC. As of May 12, 2020, the vaccine is subject to approval by Health Canada for a Clinical Trial Application being filed by CanSinoBIO. As a preparatory step the Government of Canada announced $44 million in funding to support upgrades to NRC facilities in Montreal to ensure readiness for Canadian bioprocessing of potential vaccine candidates.

This text snippet is from the topic CanSino BiologicsCanSino Biologics
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.